ACH-0143102 + ribavirin

ACH-0143102 + ribavirin is an **investigational oral combination therapy** for chronic hepatitis C virus (HCV) infection, specifically evaluated in treatment-naive patients with HCV genotype 1b. ACH-0143102 is a novel nonstructural protein 5A (NS5A) inhibitor, which blocks a critical viral protein required for HCV replication, while ribavirin is a nucleoside analogue antiviral that promotes lethal mutagenesis of viral RNA and is commonly used as adjunctive therapy alongside other direct-acting antivirals. This combination was assessed for safety, tolerability, and efficacy (rate of virologic response) in clinical trials, but does not appear to have advanced to further development or become an approved therapy[1][3][4][8].